Sign inJoin waitlistJoin the waitlist

Peter Voorhees

Co-Leader · Wake Forest University Baptist Medical Center

Credentials: · · ·

History

Wake Forest University Baptist Medical Center
Present
Wake Forest University Baptist Medical Center
Present

University of North Carolina School of Medicine
2000–2003
Internal Medicine
University of Wisconsin Hospitals and Clinics
1997–2000
University of Michigan Medical School
1993–1997

Research

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
The Lancet · 2016 · 711 citations
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
The Lancet Oncology · 2020 · 657 citations
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
Blood · 2007 · 625 citations

Saad Usmani
45 papers
Shebli Atrash
40 papers · 21 as a resident
Paul Richardson
36 papers
Robert Orlowski
31 papers
Douglas Sborov
30 papers
Manisha Bhutani
30 papers · 3 as a fellow
Larry Anderson
29 papers
Christopher Ferreri
22 papers · 8 as a fellow
Jacob Laubach
20 papers
Ajai Chari
19 papers
LS
Leyla Shune
19 papers
Barry Paul
18 papers · 6 as a fellow

Grants

General Clinical Research Center
National Center for Research Resources · M01
Project lead · $8.4K · Univ of North Carolina Chapel Hill
2005–2008
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $714.4K · Univ of North Carolina Chapel Hill

Clinical trials

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
Principal investigator · Withdrawn · Phase 2
UNC Lineberger Comprehensive Cancer Center
2012–2017
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
Study chair · Unknown · Phase 1, Phase 2
Alliance for Clinical Trials in Oncology
2014
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Site PI · Unknown · Phase 1, Phase 2
Prolexys Pharmaceuticals
2012–2014